AU2002343085A1 - Tnf-alpha inhibitors for the treatment of hepatic diseases - Google Patents

Tnf-alpha inhibitors for the treatment of hepatic diseases

Info

Publication number
AU2002343085A1
AU2002343085A1 AU2002343085A AU2002343085A AU2002343085A1 AU 2002343085 A1 AU2002343085 A1 AU 2002343085A1 AU 2002343085 A AU2002343085 A AU 2002343085A AU 2002343085 A AU2002343085 A AU 2002343085A AU 2002343085 A1 AU2002343085 A1 AU 2002343085A1
Authority
AU
Australia
Prior art keywords
tnf
treatment
hepatic diseases
alpha inhibitors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002343085A
Inventor
Gabriel Stavros Panayi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Publication of AU2002343085A1 publication Critical patent/AU2002343085A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU2002343085A 2001-11-23 2002-11-25 Tnf-alpha inhibitors for the treatment of hepatic diseases Abandoned AU2002343085A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0128138.5 2001-11-23
GBGB0128138.5A GB0128138D0 (en) 2001-11-23 2001-11-23 Pharmaceutical use
PCT/GB2002/005300 WO2003045430A1 (en) 2001-11-23 2002-11-25 Tnf-alpha inhibitors for the treatment of hepatic diseases

Publications (1)

Publication Number Publication Date
AU2002343085A1 true AU2002343085A1 (en) 2003-06-10

Family

ID=9926358

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002343085A Abandoned AU2002343085A1 (en) 2001-11-23 2002-11-25 Tnf-alpha inhibitors for the treatment of hepatic diseases

Country Status (3)

Country Link
AU (1) AU2002343085A1 (en)
GB (1) GB0128138D0 (en)
WO (1) WO2003045430A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
CA2566975A1 (en) * 2004-06-04 2005-12-15 Apoxis Sa Method to reduce hepatotoxicity of fas-mediated apoptosis-inducing agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6107273A (en) * 1995-01-24 2000-08-22 Thomas Jefferson University Tumor necrosis factor inhibitors
US5753628A (en) * 1995-06-07 1998-05-19 Centocor, Inc. Peptide inhibitors of TNF containing predominantly D-amino acids
PT936923E (en) * 1996-11-15 2004-04-30 Kennedy Inst Of Rheumatology BLENDING OF TNFALFA AND IL-12 IN THERAPY
WO1999009965A2 (en) * 1997-08-21 1999-03-04 Takeda Chemical Industries, Ltd. Anti-inflammatory agent
US6455528B1 (en) * 1997-10-14 2002-09-24 Mitsubishi Pharma Corporation Piperazine compounds and medicinal use thereof
JPH11127882A (en) * 1997-10-27 1999-05-18 Nippon Kayaku Co Ltd Novel physiologically active substance nk30424a and nk3024 b, their production and use
JPH11228576A (en) * 1997-12-10 1999-08-24 Japan Tobacco Inc Apoptosis inhibitor
FR2779724B1 (en) * 1998-06-10 2001-04-20 Rhone Poulenc Rorer Sa PYRROLE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AU4363200A (en) * 1999-04-19 2000-11-02 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
JP2001081088A (en) * 1999-09-10 2001-03-27 Nippon Kayaku Co Ltd New physiologically active substance nk3042 analogue and production and use thereof

Also Published As

Publication number Publication date
WO2003045430A1 (en) 2003-06-05
GB0128138D0 (en) 2002-01-16

Similar Documents

Publication Publication Date Title
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
PL362711A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases
WO2003033720A8 (en) Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
GB0329874D0 (en) Compounds useful for the treatment of diseases
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
PT1487828E (en) Morpholinyl-urea derivatives for use of the treatment of inflamatory diseases
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
AU2003260778A1 (en) Treatment of pipes
AU2003291886A1 (en) Thiophenederivatives for the treatment of flavivirus infections
AU2003223538A1 (en) Methods for the treatment of cancer
AU2003270683A1 (en) Compounds for the treatment of premature ejaculation
AU3004000A (en) Methods for the treatment of apolipoprotein e related diseases
AU2002258798A1 (en) Methods for the treatment of hepatic disorders
AU2002359635A1 (en) Use of polycyclic phenolic compounds for the treatment of opthalmic diseases
AU2002343085A1 (en) Tnf-alpha inhibitors for the treatment of hepatic diseases
GB0201025D0 (en) The treatment of degenerative diseases
AU2003264954A1 (en) Pharmaceutical composition for prevention and treatment of kidney diseases
AU2002364774A1 (en) Ilk inhibitors for the treatment of renal disease
AU2003240174A1 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AU2003236787A1 (en) Use of alkylphosphocholines for the preventative treatment of protozoan diseases
EP1488800A4 (en) Agent for the treatment of protozoal diseases
AU2003232844A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases
AU2003208809A1 (en) Treatment of neuroblastoma
AU2002344959A1 (en) Use of fasl for the treatment of neurodegenerative diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase